Our cost-effectiveness study aimed to assess the economic implications of PGx-guided testing, particularly targeting CYP2D6 and CYP2C19 genes, in MDD patients initiating antidepressant therapy. This evidence concerns the gene CYP2C19 and major depressive disorder.